Ernexa TherapeuticsERNA +3.68%30 PB Ratio is 1.03 as of Jul. 12, 2026, which is 62% below its 10-year median of 2.68. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,231 Biotechnology companies, Ernexa Therapeutics ranks better than 82.45% on this metric.
The historical rank and industry rank for Ernexa Therapeutics's PB Ratio or its related term are showing as below:
ERNA'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 2.68 Max: 17.11
Current: 1.03
During the past 6 years, Ernexa Therapeutics's highest PB Ratio was 17.11. The lowest was 0.34. And the median was 2.68.
ERNA's PB Ratio is ranked better than 82.45% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs ERNA: 1.03
During the past 3 years, the average Book Value Per Share Growth Rate was -79.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -71.80% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Ernexa Therapeutics was -50.00% per year. The lowest was -85.00% per year. And the median was -79.30% per year.
Back to Basics: PB Ratio
Ernexa Therapeutics (NAS:ERNA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ernexa Therapeutics PB Ratio Related Terms
Ernexa Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Ernexa Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ernexa Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ernexa Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ernexa Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ernexa Therapeutics (ERNA) has a PB Ratio of 1.03 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ernexa Therapeutics and its competitors. This is 62% below median its historical median of 2.68. Over the past decade, Ernexa Therapeutics' PB Ratio has ranged from 0.34 to 17.11. According to the industry distribution chart, Ernexa Therapeutics ranks #216 out of 1231 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Ernexa Therapeutics' PB Ratio too high?
Ernexa Therapeutics' current PB Ratio of 1.03 is 62% below median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 17.11. The Biotechnology industry median PB Ratio is 2.93. Ernexa Therapeutics' value of 1.03 is 64.8% below this industry median. Based on the distribution chart, Ernexa Therapeutics ranks #216 out of 1231 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' PB Ratio compare to PMCB and SYBX?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #216 out of 1231 companies for PB Ratio. This places Ernexa Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.93. Ernexa Therapeutics' value of 1.03 is 64.8% below this benchmark. Historically, Ernexa Therapeutics' own PB Ratio has ranged from 0.34 to 17.11 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 2.93, Ernexa Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ernexa Therapeutics's current PB Ratio of 1.03 is 64.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ernexa Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ernexa Therapeutics's current PB Ratio is 1.03, which is 62% below median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current PB Ratio of 1.03. The current PB Ratio is 1.03, which is 62% below median its 10-year median of 2.68 and 64.8% below the Biotechnology industry median of 2.93. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current PB Ratio is 1.03 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score
Get the complete analysis for ERNA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERNA has been successfully added to your 
